ABUS - Arbutus Biopharma GAAP EPS of -$0.10 beats by $0.04 revenue of $6.7M beats by $0.67M

2023-05-04 07:45:26 ET

• Arbutus Biopharma press release ( NASDAQ: ABUS ): Q1 GAAP EPS of -$0.10 beats by $0.04 .
• Revenue of $6.7M (-46.7% Y/Y) beats by $0.67M .
• As of March 31, 2023, company had cash, cash equivalents and investments in marketable securities of $178.5 million compared to $184.3 million as of December 31, 2022.
• Research and development expenses were $18.3 million for the three months ended March 31, 2023 compared to $18.5 million for the same period in 2022.

For further details see: